Abstract
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the
pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and
Kalorama Information believes this product management tactic will continue to
be aggressively utilized as companies seek ways to extend revenue life.
Kalorama Information' s The Return of the Rx to OTC Switch: Market Analysis and
Product Management Strategies contians a complete overview of the market for
prescription drugs likely to switch in the following drug categories:
- Allergy and Cold
- Antilipidemic Agents
- Fungal Infections
- Gastrointestinal Drugs
- Hair Loss Treatments
- Migraine Therapy
- Nonsteroidal Anti-inflammatories
- Oral Contraceptives
- Osteoporosis and Hormone Replacement Therapies
- Overactive Bladder
- Sexual Dysfunction
- Sleep Agents
- Smoking Cessation
- Viral Infections
- Others
Kalorama Information believes this trend of utilizing Rx to OTC will continue.
There are currently 14 prescription drugs, with worldwide prescription sales
exceeding $20 billion in 2006, with the potential to reach the OTC market by
the year 2013.
What are the most viable products that are candidates for Rx to OTC switches?
Who are the players in the industry best suited to execute this strategy? What
is the market potential for Rx to OTC in key categories? And what are the
advantages and pitfalls of using this tactic in the current market? These
questions and more are answered in this Kalorama Information report, the
result of Moutaintop Medical' s exhaustive analysis and interviews with experts
in the industry.
View Cart
